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Abstract (Word Count 298) 
Objectives:  The objective of this 30-week randomized crossover trial was to determine 
whether a multi-modal realignment therapy would be successful in relieving pain and improving 
function among persons with medial tibiofemoral OA.   
METHODS:  We conducted a double blind, randomized crossover trial of a multi-modal 
realignment therapy for persons with medial tibiofemoral OA. Trial participants met ACR criteria 
for OA with knee pain, aching or stiffness on most days of the past month and radiographic 
evidence of a definite osteophyte with predominant medial tibiofemoral OA. We tested two 
different treatments: A) CONTROL TREATMENT consisting of a neutral knee brace (no valgus 
angulation), flat unsupportive foot orthoses, and shoes with a flexible midsole; and B) ACTIVE 
TREATMENT consisting of a valgus knee brace, customized neutral foot orthoses, and shoes 
designed for motion control. For each subject, the trial lasted 30 weeks, including 12 weeks 
each of active and control treatment separated by a 6-week washout period. The primary 
outcome of the linear regression model was change in knee pain and function as assessed by 
the WOMAC Osteoarthritis Index.   
RESULTS: 80 participants with medial tibiofemoral OA were randomized. Their mean age was 
62 years, mean BMI was 34 kg/m2 and mean WOMAC pain score was 9.2 (0-20 scale). There 
was no evidence of a carryover effect. The regression model demonstrated that the mean 
difference in pain between the active and control treatments was -1.82 units (95% confidence 
interval: -3.05 to -0.60 [p=0.004]) on the WOMAC pain scale, indicating a small, but statistically 
significant decrease in pain with the multi-modal active treatment. For WOMAC function the 
realignment intervention had a non-significant effect on function with a -2.90 unit decrease (95% 
CI -6.60 to 0.79) compared with the control condition (p=0.12). 
CONCLUSION: Multi-modal realignment therapy decreases pain in persons with medial 
tibiofemoral OA.  
 
NIH Clinical Trials Registry NCT00124462 
Supported by NIDRR (Grant no. H133G040201) and DonJoy 
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Introduction 
The etiopathogenesis and progression of  symptomatic knee osteoarthritis (OA) is driven by 
mechanical factors 1. A number of biomechanical studies have demonstrated improvements in 
certain aspects of gait and biomechanics with valgus bracing among persons with knee 
osteoarthritis (OA) 2-4. In addition, numerous randomized controlled trials (RCT) have 
investigated the clinical effects of valgus bracing in improving pain and function outcomes 
among persons with symptomatic knee OA 3;5-15. While the findings have generally been 
supportive, several study design limitations, including the studies being uncontrolled 5-10 and/or 
underpowered 11-15, have called the results of these few RCTs into question 16;17.  
The two largest studies to date have suggested positive effects on symptoms. Kirkley et al 18 
found significant improvements in the braced treatment group compared with an unbraced 
control group. However, this trial may not have been appropriately controlled since an active 
brace intervention was compared to no intervention at all 18. Given the profound effects of 
placebo in OA 19, and the potential for symptomatic improvements with neoprene sleeve 
interventions alone 20, the findings of the Kirkley trial require confirmation. A more recent RCT 
by Brouwer et al 21 found that valgus knee bracing resulted in improved knee function but no 
significant improvements in knee pain compared with no bracing. However, many participants in 
the Brouwer trial did not fully adhere to brace treatment as a result of skin irritation and poor fit.  
Given the findings of previous trials have been somewhat equivocal, disease management 
guidelines have not advocated for the use of braces and have recommended further research is 
needed 17. Echoing this need, recent systematic reviews of unloader braces for knee OA found 
modest evidence for their effectiveness and also recommended that further research be 
conducted 3;16. Hence the need for an appropriately powered and well-controlled trial of the 
effect of valgus knee bracing among persons with medial knee OA.   
Unfortunately, biomechanical studies demonstrate that even with appropriate valgus bracing, 
large mechanical stresses on the knee can persist, suggesting that the addition of other 
interventions to further improve limb alignment may be of therapeutic value 9. Multiple orthotic 
modalities to decrease forces across a knee may be necessary in order to fully unload an 
osteoarthritic medial compartment and bring about significant improvements in knee pain and 
function. Recognizing the relationship between knee and foot biomechanics 22, the combination 
of a valgus knee brace with motion-control shoes and neutral foot orthoses has been proposed 
as a promising multi-modal strategy [3]. 
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The overall objective of this study was to determine whether, among patients with medial 
tibiofemoral OA, the provision of a multi-modal realignment therapy relieves knee pain and 
improves function in a 30-week randomized crossover clinical trial.  We tested the 
hypothesis that, compared to control treatment, a multi-modal realignment therapy that 
includes a valgus knee brace, motion control shoes, and neutral foot orthoses 
(customized shoe inserts) is effective in reducing pain and improving function among persons 
with medial tibiofemoral OA.   
 
Materials and Methods 
Design Overview 
This study was a double blind (participant and assessor), randomized crossover trial of a 
realignment therapy for patients with medial tibiofemoral osteoarthritis with the primary outcome 
being knee pain and function as assessed by the WOMAC Osteoarthritis Index (VAS Version) 
23.  The trial was prospectively registered with the NIH Clinical Trials Registry NCT00124462 
and approval was given by the Boston University IRB and the New England Baptist Hospital 
IRB. All participants provided written informed consent. The study conformed to the CONSORT 
requirements for RCTs. Study design and protocol development began in January 2005. 
Recruitment and enrolment began in June 2005. Follow-up of all subjects was completed in 
September 2008. 
Given the possibility that even braces with no realigning capabilities can provide sensory input 
and improve symptoms on that basis alone, we compared the effects of the active brace 
treatment to the effects of a control treatment consisting of comparable braces without 
realigning capabilities:  
1. CONTROL TREATMENT (A): A neutral knee brace that does not have 
any varus/valgus angulation was given along with flat, unsupportive foot orthoses 
and shoes with a flexible midsole. 
2. ACTIVE TREATMENT (B): A valgus knee brace was given with 
customized neutral foot orthoses and motion control shoes.  
A run-in design was used in order to maximize the likelihood of recruiting subjects who would 
remain in the trial.  Subjects were randomized to receive either brace treatment A or brace 
treatment B for the initial 12 weeks. After 12 weeks, we removed the assigned brace, and 
participants received no therapy for 6 weeks. Following this 6-week wash-out period, the 
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alternative brace treatment was assigned for the final 12 weeks. For each subject, the trial 
lasted a total of 30 weeks.  
Intervention (Figure 1) 
The active treatment consisted of a DonJoy OAdjuster knee brace (DonJoy Braces, Inc., 
Coconut Creek, FL) with bilateral customized semi-rigid functional foot orthoses which were 
crafted according to methods previously described 24 using heat-moldable Fastech (Fastech 
Labs, Inc., Troy, MI) shells and medium density Nickleplast-S (Alimed, Inc., Dedham, MA) 
inners to support a neutral foot position. The custom made foot orthoses replaced the normal 
insoles of a New Balance 830 motion control shoe (New Balance, Inc., Brighton, MA). The 
control brace consisted of the DonJoy Montana brace with a loosened screw at the hinge 
allowing varus-valgus laxity, a flat unmolded 1/16” FastTech Orthotic Blank of an identical 
material (Poron) to the active treatment but without the heat moldable core, and a New Balance 
court shoe (model 505) with a low density midsole and flexible upper to minimize motion control. 
Shoes and orthoses were worn on both feet during each treatment period. 
Eligibility Criteria: 
Trial participants met ACR criteria for osteoarthritis with knee pain, aching or stiffness on most 
of the past 30 days and evidence on radiograph of a definite osteophyte.  In addition, because 
we were interested in persons with predominantly medial tibiofemoral osteoarthritis, 
participants had radiographic evidence of disease in the medial tibiofemoral compartment 
without predominant lateral tibiofemoral or patellofemoral involvement. Medial tibiofemoral 
disease 25 required definite radiographic OA with at least grade 1 medial joint space narrowing 
(0-3 scale) using the Osteoarthritis Research Society International  (OARSI) atlas 26.  Individuals 
with clinical evidence of patellofemoral disease or knee pathology (other than medial 
compartment OA) that was likely to be contributing to their knee pain (such as pes anserine 
bursitis) were excluded. Participants had to be ambulatory and limited in usual activities due to 
knee pain. The anatomic axis was measured from the short films using previously validated 
methods 27. 
Exclusion criteria included: 1) Individuals who usually used an ambulation aid to walk, such as 
a cane, crutch, walker or wheelchair; 2) Amputation of a foot or previous major trauma to a foot 
that would raise concerns about whether an orthosis might worsen foot pain; 3) Known 
neuropathy due to diabetes or other causes; 4) Past history of deep vein thrombosis; 5) Pain 
emanating more from the back or hip than from knee as determined by a screening 
questionnaire and clinic exam; 6) Planning to move from the area within 9 months of study 
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screening; 7) Symptomatic comorbid disease that limits walking more than knee pain; 8) 
Receiving corticosteriod injections in the knee in the month prior to starting the trial; 9) For 
participants on glucosamine and/or chondroitin and/or NSAID, we required that they must be on 
a stable dose for at least 2 months prior to beginning the trial and commit to not starting any 
new treatments during the trial; 10) Bilateral total knee replacements (TKR) or plan for TKR of 
the index knee in next 6 months; 11) Other known causes of arthritis including rheumatoid 
arthritis, SLE, gout, psoriatic arthritis, and pseudogout; or 12) Failure to pass the 2 week run-in 
test; 13) Height of 5'0'' or less due to incompatibility with brace fitting; 14) Past use of 
prescription brace or custom orthotic. 
Additionally persons with low WOMAC pain scores at the time of pre-randomization screening 
were excluded. In order to properly evaluate response to treatment, we required that patients 
have a minimal score of at least 2 out of 5 on at least 2 of the 5 WOMAC questions, or a total of 
greater than 6 out of 20 on the WOMAC pain scale in the index knee during both a pre-
randomization phone call and a screening visit. In the event that both knees met all eligibility 
criteria, the most symptomatic knee served as the index knee. 
Recruitment 
Participants were recruited using various forms of advertising in local public media, from 
among patients in the rheumatology and orthopedic sections of Boston Medical Center and New 
England Baptist Hospital, and from persons already recruited for other clinical trials. 
The efficacy of a clinical trial is maximized if subjects comply with assigned treatment and 
come to scheduled visits.  One way to increase the likelihood of subject compliance with a trial 
is to perform a run-in test, a period of observation prior to randomization during which subjects 
get experience with major components of the study protocol.  Those subjects who have trouble 
complying with the protocol are excluded before being randomized. Participants had a 2-week 
placebo run-in 28 with administration of the control shoe and control foot orthosis. Blindness 
was re-assessed at the beginning of the study and equal numbers of participants considered the 
control shoe and orthosis active and placebo interventions respectively. 
We preserved allocation concealment by having the randomization codes held by a 
biostatistician at the Boston University School of Public Health, which is external to the Clinical 
Epidemiology and Research Training Unit where the trial examiners were located. We stratified 
patients into those with end stage (Kellgren & Lawrence Grade 4) OA and those with disease 
that was mild or moderate yet still predominantly affecting the medial joint.  We then performed 
Manuscript draft 150112 
7 | P a g e  
 
computer generated blocked stratified randomization in order to ensure that roughly equal 
numbers of patients with severe and mild / moderate disease were randomized into each of the 
two treatment arms. The enrolment of participants and their assignation to intervention were 
conducted by separate research coordinators. 
   Blinding 
Participants were told only that we were comparing two types of treatment for their knee 
arthritis. We did not specify which therapy constituted active treatment.  A single blinded 
examiner administered the knee pain and function outcome measures, while a second 
investigator with experience in foot orthotic customization (KDG) fitted the shoe and customized 
the foot orthoses.  
Adherence 
We applied a number of different methods to monitor and improve adherence. Educational 
messages on the potential benefits of non-pharmacologic therapy and skills training on donning 
the alignment therapies were discussed and provided to participants to increase confidence and 
motivation to comply 29-31.  We inquired in a detailed fashion into adherence during each 
visit.  To assess adherence, we called the subjects every week during the active phases of the 
trial (Phase 1: 0-12 weeks (visits occurred at 0, 1, 3, 6 and 12 weeks); and Phase 2: 18-30 
weeks (visits occurred at 18, 19, 21, 24 and 30 weeks)). In addition, subjects kept a diary 
recording their daily use of the combination of brace, shoes and insert during the course of the 
trial, and a pamphlet was issued which addressed common concerns that might interfere with 
adherence. Participants were encouraged to wear the interventions for a minimum of 4 hours 
per day. 
Study Outcomes  
The primary outcomes were the WOMAC Pain and Function Subscales 23. The WOMAC, 
which has been extensively validated and is recommended by the OARSI for use in OA clinical 
trials, has three subscales: the pain (5 items) subscale, the stiffness (2 items) subscale, and the 
physical function (17 items) subscale.  In this study, results on the pain and physical function 
subscales were analyzed separately. All of the subscales have high test-retest reliability, and 
validation studies have shown high correlations with other indices probing similar constructs 23.  
In terms of responsiveness to change, the WOMAC has been compared to other measures of 
patient status in OA including the Doyle index, the Lequesne index, walk time and range of 
motion 32-35 and has generally been found to be more responsive than these other instruments.   
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Statistical Analysis   
Analysis of this trial focused on the primary outcome measure, which was change in WOMAC 
pain during treatment. The primary study question was whether the change in pain during the 
active treatment period differed from the change in pain during the control treatment period. We 
made similar comparisons of changes in WOMAC function scores during the active and control 
treatment periods. 
We performed regression analysis of the relationship between treatment type (active or 
control) and WOMAC pain and function scores during the treatment period. We used a GEE 
(Generalized Estimating Equations) correction to account for repeated measures within 
individual participants. These methods were similar to those used in a prior crossover trial in OA 
36. Additional regression models were constructed using an interaction term of treatment by 
period as predictors. In a two-period crossover trial, the treatment by period interaction is 
equivalent to the carryover effect, so this provided a method of assessing carryover effect. The 
washout period of six weeks between treatment periods was intended to reduce the likelihood of 
a carryover effect. This analysis used an intent-to-treat approach with the last observation 
brought forward for missing values.  
All statistical analyses were performed using version 9 of the SAS statistical analysis software 
package. The GENMOD procedure was used for regression analyses with GEE corrections for 
repeated measures.    
Statistical power estimates: Based on the results from the Horlick 15 and Kirkley 18 trials of 
valgus knee bracing, we anticipated a conservative treatment effect difference of 30% in pain 
and function. We estimated a correlation of 0.6 in the primary outcome measure (WOMAC pain) 
for measures taken within a subject.  With 80 participants, we had 80% power (with an alpha of 
0.05 in a 2-sided test) to detect a treatment effect of 30% reduction of WOMAC pain compared 
with the control condition.  
 
Results 
Of the 860 potential participants who were contacted by phone, 229 were eligible for a 
screening visit. The most common reason for ineligibility was insufficient pain. Of the 150 
participants who had a screening visit, 80 were found to be eligible and were randomized. Of 
the 80 participants enrolled, 56 completed the study (Figure 2). The main reasons for early 
termination were loss to follow-up, non-compliance, and scheduled joint replacement. 
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There were no statistically significant differences in age, gender, BMI, or radiographic severity 
between those who were randomly assigned to receive the active treatment first and those who 
were randomly assigned to receive the control treatment first (Table 1). Baseline WOMAC pain 
score was slightly higher in the group randomized to the active treatment first. 
When analyzing the crossover trial findings for pain, we first tested for treatment period and 
differential carryover effects (Table 2 and Figure 3). The treatment period effect was a 0.43 unit 
difference (p = 0.66) in WOMAC pain change score, and the differential carryover effect was 
only a -0.10 point difference in the WOMAC pain change score (p = 0.95), indicating that 
treatment effectiveness did not depend on whether a participant was randomized to the active 
or control treatments first. Therefore, we removed the carryover term from the model. In Model 2, 
excluding the differential carryover effect, the realignment intervention had a significant effect on 
pain with a -1.82 unit decrease in pain (95% CI -3.05 to -0.6) compared with the control 
condition (p = 0.004). 
For WOMAC function, the treatment-period effect was a 0.58unit difference (p = 0.84) (Table 
3 and Figure 4), and the differential carryover was a 0.99 unit difference on the 68-unit WOMAC 
function scale (p= 0.82), indicating once again that treatment effectiveness did not depend on 
whether a participant was randomized to the active or control treatments first. Therefore, we 
removed the carryover term from the model. In Model 2, excluding the differential carryover 
effect, the realignment intervention had a non-significant effect on function with a -2.90 unit 
decrease (95% CI -6.60 to 0.79) compared with the control condition (p=0.12). 
To facilitate understanding of the phase specific effects (consistent with Figures 3 and 4) we 
have inserted additional information about pain and function by phase (Table 4). This 
incorporates the carryover effect test and the estimated treatment effect from model 2(without 
carryover effect) from Tables 2 and 3. The results are consistent with a favorable effect for 
realignment compared to placebo in each treatment phase. 
The adherence of study participants and reported side effects are detailed in Table 5. On 
average, participants wore the interventions for more than 3 hours per day. The most frequent 
side effect reported among persons wearing the realignment therapy compared to the control 
was problems with brace positioning or slipping (16 participants compared to 4 in the placebo 
group). Participants also more frequently reported pain from poorly fitting shoes during the 
active treatment period (7 participants compared to 1 during the control period). 
 
Manuscript draft 150112 
10 | P a g e  
 
Discussion 
The need to develop efficacious, conservative, non-pharmacologic treatment approaches that 
are capable of ameliorating the symptoms of people with knee OA is an important research 
objective 37. Despite insufficient attention from researchers and clinicians, therapies capable of 
targeting the pathomechanics of OA are likely to be efficacious 38. We have demonstrated that 
the application of realignment therapy consisting of a DonJoy OAdjuster knee brace, 
customized foot orthoses, and New Balance 830 motion control shoes leads to a statistically 
significant improvement in knee pain compared to a placebo intervention. 
The direction of effect (a 1.8 unit reduction in WOMAC pain) is consistent with the positive 
effects seen in other randomized trials of knee braces 15;18;21. However, the magnitude of effect 
(~20% reduction in pain from baseline) is slightly less than that seen in previous brace trials. 
This discrepancy may result from differences in study design and the particular interventions 
tested. First, our study intervention involved not just a brace but also a motion control shoe and 
a foot orthosis. Two previous trials demonstrated that wearing a valgus knee brace alone can 
result in substantial improvements in the pain and function of patients with medial knee OA 15;18. 
However, in contrast to these two previous trials, we also employed a rigorous control 
intervention, making demonstration of a sizable treatment effect more challenging. A third trial 
by Brouwer et al 21 failed to demonstrate the efficacy of unloader bracing (either varus or valgus) 
within a study sample that included persons with both lateral and medial tibiofemoral OA. 
Among the possible reasons for failure to demonstrate treatment efficacy in the Brouwer trial 
were problems with adherence to brace treatment, mainly because of skin irritation and poor fit. 
Subgroup analysis of persons with medial knee OA did find significant improvements in function 
among persons who were braced. In addition we have conducted a placebo controlled trial 
where the control group received similar intervention and equal attention as the intervention 
group. Hence, what we have is the specific treatment effect distinct from the placebo effect. The 
placebo effects for self-reported outcomes such as pain and function in OA trials is substantial 39. 
This is a challenging aspect of trials particularly of non-pharmacologic treatments such as this 
trial 40. 
The medial compartment of the knee absorbs 60-70% of the force across the joint during 
weight bearing 41;42. The overwhelming majority of treatments available for OA involve drugs 
and/or surgery.  Despite strong evidence for the potent effect of mechanics (in particular, the 
external knee adduction moment) on disease progression and symptoms 38;43-47, there are few 
interventions that effectively reduce mechanical load. Our study results provide further evidence 
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that an intervention targeted to the reduction of mechanical load can have a durable therapeutic 
benefit with non-serious side effects that were largely managed with training or other minor 
adjustments. 
There are a number of limitations of this study that warrant discussion. First, there was no 
control group without an intervention because of concerns about unblinding.  Prior research has 
highlighted the difficulty of disentangling the placebo effect in non-pharmacologic clinical trials 
40;48;49. Consistent with this prior research, participants in the current crossover trial experienced 
symptomatic improvement during both the active and control intervention periods, making it 
more challenging to detect a relative improvement during the active intervention. There were 
also a number of dropouts in the trial. Most dropouts occurred during the second treatment 
condition, and efforts to reduce the impact of this censored data using an intent-to-treat analysis 
were applied 50. Lastly, the daily duration of optimal treatment is unknown for this type of 
intervention, and therefore the prescribed 4 hours of daily use in this study was largely arbitrary. 
In the clinic, braces are often prescribed for use only during aggravating weight bearing 
activities. 
There are also a number of important strengths of this study that merit discussion. The 
crossover design facilitates efficient recruitment and protection against confounding by patient-
related factors. Similarly, we were adequately powered to detect a clinically meaningful 
treatment effect. The effect we found while statistically significant approximates that of clinical 
significance. Reports of the minimum clinically important difference in pain using the WOMAC 
suggest values reporting an improvement of 10-20% are of clinical importance 51;52. It is possible 
that treatment effects may differ according to baseline alignment or radiographic severity. We 
are currently undertaking further research in this sample to determine if that is the case. 
Multi-modal realignment therapy has significant effects on pain in persons with medial 
tibiofemoral OA. Further studies of this intervention are warranted to corroborate our findings. In 
addition, biomechanical studies that include clinical outcome measures will be helpful in 
determining whether clinical improvement is a function of mechanical alterations. 
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Table 1. Characteristics of the participants at baseline 
 
Characteristics Realignment 
to placebo 
(n=40 ) 
Placebo to 
realignment 
(n= 40) 
Age, mean _ SD years 63 (10.8) 60 (13.1) 
Male sex, % 15 (37.5%) 15 (37.5%) 
Body mass index, mean _ SD kg/m2 32.7 (8.4) 34.7 (10.8) 
Kellgren/Lawrence grade ≥3, %  39 (97.5%) 40 (100%) 
Kellgren/Lawrence grade _2, % 1(2.5%) 0 
Kellgren/Lawrence grade _3, % 25(62.5%) 28(70%) 
Kellgren/Lawrence grade _4, % 14(35%) 12(30%) 
Medial JSN Grade 0, % 1(2.5%) 0 
Medial JSN Grade 1, % 9(22.5%) 10(25%) 
Medial JSN Grade 2, % 14(35%) 16(40%) 
Medial JSN Grade 3, % 16(40%) 14(35%) 
Anatomic axis (degrees) 1.0(3.9) 
Median=1 
0.7(5.3) 
Median=0 
Contralateral knee Kellgren/ Lawrence 
grade≥2, % 
32(80%) 30(75%) 
WOMAC pain score, mean _ SD (0–20 scale) 9.2 (3.4) 9.1 (3.4) 
WOMAC Function score, mean _ SD (0–68 
scale) 
33.3(11.8) 34.6(10.3) 
* WOMAC _ Western Ontario and McMaster Universities Osteoarthritis Index. 
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Table 2. Predictors of WOMAC pain scores during the crossover trial* 
 
Predictor Model 1  Model2 
Active Treatment  
 (95% confidence interval) 
p-value 
-1.78 
-3.66, 0.11 
0.06 
-1.82 
-3.05, -0.60 
0.004 
Treatment, period 1 vs. period 2  
(95% confidence interval) 
p-value 
-0.43 
-2.38, 1.52 
0.66 
0.38 
-1.61, 0.85 
0.54 
Carryover effect †  
(95% confidence interval) 
p-value 
0.10 
-2.94, 3.14 
0.95 
 
 
* Values for model predictors are beta coefficients. For treatment as a predictor, a value of x 
means that active treatment was associated with a x lower score on the Western Ontario and 
McMaster Universities Osteoarthritis Index (WOMAC) pain scale compared with control 
treatment. An unstructured correlation matrix for observations within subjects was used in 
generalized estimating equation fitting of the marginal model (1). Model 2 was conducted with 
exclusion of the differential carryover effect. 
† Tests whether treatment effects differed according to use in period 1 or period 2, constituting 
the differential carryover effect. 
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Table 3. Predictors of WOMAC function scores during the crossover trial* 
Predictor  Model 1   Model2  
Active treatment  
(95% confidence interval)  
p-value  
-2.56  
(-7.35, 2.24)  
0.29  
-2.90  
(-6.60, 0.79)  
0.12  
Treatment, period 1 vs. period 2  
(95% confidence interval)  
p-value  
-0.58 
(-5.23, 6.40)  
0.84  
-0.09 
(-4.00, 3.82)  
0.96 
Carryover effect † 
 (95% confidence interval)  
p-value  
0.99 
(-7.70, 9.68)  
0.82  
 
* Values for model predictors are beta coefficients. For treatment as a predictor, a value of x 
means that active treatment was associated with a x lower score on the Western Ontario and 
McMaster Universities Osteoarthritis Index (WOMAC) pain scale compared with control 
treatment. An unstructured correlation matrix for observations within subjects was used in 
generalized estimating equation fitting of the marginal model (1). Model 2 was conducted with 
exclusion of the differential carryover effect. 
† Tests whether treatment effects differed according to use in period 1 or period 2, constituting 
the differential carryover effect. 
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Table 4. Phase specific effects of each intervention§ 
 
Treatment 
Phase1 Phase2 Both Phases 
Carryover 
effect test Mean 
change(SD) 
Estimated 
Diff(SE) 
Mean 
change(SD) 
Estimated 
Diff(SE) 
Mean 
change(SD) 
Estimated 
Diff(SE) 
WOMAC 
Pain 
Realignment -2.2(3.3) -1.9(1.01) 
p=0.068 
-1.7(3.8) -1.8(0.9) 
p=0.064 
-2.0(3.5) -1.8(0.6) 
p=0.004 
0.10(1.5) 
p=0.947 Placebo -0.3(4.3) 0.03(3.2) -0.1(3.7) 
WOMAC 
Function 
Realignment -5.1(12.1) -3.5 (3.4) 
p=0.296 
-4.6(9.6) -2.6(2.4) 
p=0.290 
-4.9(10.9) -2.9(1.8) 
p=0.121 
-0.99(4.3) 
p=0.82 Placebo -2.0(8.4) -1.6(13.1) -1.8(10.8) 
§ Incorporates the carryover effect test and the estimated treatment effect from model 2(without 
carryover effect) 
Manuscript draft 150112 
17 | P a g e  
 
Table 5. Adherence to and side effects of treatment 
 Realignment  Placebo  
Adherence, mean _ SD 
hours of wear/day 
  
Period 1 3.32(1.55) 3.99(2.82) 
Period 2 3.35(2.39) 3.29(1.92) 
Side effect, no. of patients   
Brace slipping/Positioning 16 4 
Pain from shoes 7 1 
Signal knee symptoms increasing 3 6 
More pain in non-treatment knee 5 3 
Other 7 5 
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